Nuvaxovid Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to global COVID-19 pandemic response initiatives, emergency use authorizations for vaccines, expansion of large-scale immunization programs, increased public health funding, rapid scaling of vaccine manufacturing capacity.

The growth in the forecast period can be attributed to continued demand for booster immunizations, rising focus on variant-adapted vaccines, expansion of global vaccination coverage, increasing preference for diversified vaccine technologies, strengthening of pandemic preparedness strategies. Major trends in the forecast period include increasing adoption of protein-based vaccine platforms, rising focus on adjuvant-enhanced immunogenicity, expansion of cold-chain optimized vaccine distribution, growing demand for non-mrna COVID-19 vaccines, enhanced monitoring of vaccine safety and efficacy.

The rising prevalence of infectious diseases is expected to drive the growth of the Nuvaxovid market going forward. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can spread through person-to-person contact or environmental exposure. The increase in infectious diseases is driven by factors including global travel, rapid urbanization, climate change, antimicrobial resistance, and the emergence of new pathogens, all of which contribute to their expanding prevalence worldwide. Nuvaxovid plays a role in addressing the growing burden of infectious diseases by offering an effective vaccine to prevent COVID-19 and reduce transmission, thereby helping to limit the global spread of the virus. For instance, in March 2023, according to the Office for National Statistics, a UK-based government agency, COVID-19 infections rose in England, with an estimated 2.66% of the population testing positive during the week ending 13 March 2023. Infection trends were uncertain in Wales (2.41%), Scotland (2.59%), and Northern Ireland (1.42%). In England, hospital admissions for confirmed COVID-19 cases increased to 10.62 per 100,000 people by the week ending 19 March 2023, and COVID-19-related deaths in the UK rose to 619 by the week ending 17 March 2023, up from 605 the previous week. Therefore, the rising prevalence of infectious diseases is driving the Nuvaxovid market.

The increase in vaccine demand is expected to drive the growth of the Nuvaxovid market going forward. Vaccines are biological products that stimulate the immune system to recognize and protect against specific infectious diseases. The growing demand for vaccines is driven by the increasing incidence of infectious diseases, heightened public awareness of preventive healthcare, advancements in vaccine development, and a stronger focus on disease prevention. Nuvaxovid supports this rising demand by offering an updated vaccine option designed to target emerging COVID-19 variants, providing broader protection and supporting global immunization initiatives. For instance, in November 2024, according to the Centers for Disease Control and Prevention, a US-based federal agency, by October 2024, 13.7% of U.S. adults aged 18 and older had received the 2024-25 COVID-19 vaccine, while 24.5% had received the seasonal flu vaccine. Vaccination rates were highest among individuals aged 65 and older, with 29.1% receiving the COVID-19 vaccine and 43.1% receiving the flu vaccine. Therefore, the increasing demand for vaccines is driving the Nuvaxovid market.

A key trend in the Nuvaxovid market is the development of innovative vaccine solutions, such as updated COVID-19 vaccines, to improve protection against emerging variants and strengthen global vaccination efforts. Updated COVID-19 vaccines are revised formulations designed to enhance immunity against newly circulating SARS-CoV-2 variants, ensuring continued effectiveness in preventing severe illness and hospitalization. For instance, in October 2024, Novavax Inc., a US-based biotechnology company, announced that the European Commission granted marketing authorization for its updated 2024-2025 Nuvaxovid COVID-19 vaccine (recombinant, adjuvanted) for individuals aged 12 years and older in the European Union. The updated vaccine targets the JN.1 lineage and demonstrates cross-reactivity against several other variants, expanding access to improved vaccine protection and supporting ongoing global immunization efforts.

Major companies operating in the nuvaxovid market are Novavax Inc.

North America was the largest region in the nuvaxovid market in 2025. The regions covered in the nuvaxovid market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nuvaxovid market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the Nuvaxovid market by increasing costs of imported biomanufacturing equipment, recombinant protein inputs, adjuvant components, and specialized cold-chain packaging materials. Vaccine production and distribution activities in North America and Europe are most affected due to reliance on cross-border pharmaceutical supply chains, while Asia-Pacific faces cost pressures in bulk manufacturing exports. These tariffs are contributing to higher production costs and procurement challenges for public health programs. However, they are also encouraging domestic vaccine manufacturing, regional supply chain localization, and long-term investments in self-sufficient biologics production capabilities.

The nuvaxovid market research report is one of a series of new reports that provides nuvaxovid market statistics, including nuvaxovid industry global market size, regional shares, competitors with a nuvaxovid market share, detailed nuvaxovid market segments, market trends and opportunities, and any further data you may need to thrive in the nuvaxovid industry. This nuvaxovid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nuvaxovid is a protein-based vaccine that contains a recombinant spike protein derived from the SARS-CoV-2 virus along with the Matrix-M adjuvant to strengthen the immune response. It activates the immune system to identify and combat the virus, thereby providing protection against COVID-19. Nuvaxovid is given as a two-dose regimen and is authorized in multiple countries for the prevention of COVID-19 in individuals aged 12 years and above.

The main utilizations of Nuvaxovid include primary immunization, booster immunization, use in immunocompromised patients, elderly populations, pediatric immunization, and travel immunization. Primary immunization refers to the initial series of vaccine doses administered to initiate and build long-term immunity against specific infectious diseases. It is used in hospitals, clinics, ambulatory care settings, and home care. Nuvaxovid is distributed through channels such as retail pharmacies, online platforms, and government programs.

The nuvaxovid market consists of sales of nuvaxovid multidose vial and the single dose. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.